Personalized dosing strategies may be necessary for biologic therapies, especially fixed-dose options like ustekinumab, due ...
Psoriasis is a chronic autoimmune disease that causes plaque buildup on the skin and currently has no cure. Flare-ups can ...
In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...
Codex Labs has announced the launch of the first product in a new collection, KĀNGFÙ, that is focused on healing damaged skin ...
United States: Projected CAGR of 5.1%, with market value rising from USD 127.3 billion in 2025 to USD 209.4 billion by 2035, ...
The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.
THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...
"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...
FDA approves guselkumab as the first IL-23 inhibitor for children 6 years or older with plaque psoriasis or psoriatic arthritis. The FDA has approved guselkumab (Tremfya; Johnson & Johnson) for the ...
People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, a new study says. Psoriasis patients taking GLP-1 drugs had a 78% lower risk of ...
The Cigna Group (NYSE:CI) is one of the best inexpensive stocks to buy according to hedge funds. On August 29, Phothera announced that Cigna has updated its coverage policy for home phototherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback